Research Analysts Set Expectations for GANX Q3 Earnings

Key Points

• HC Wainwright has reduced its Q3 2025 earnings estimate for Gain Therapeutics to ($0.16) EPS, down from a previous estimate of ($0.14).
• The company's recent earnings report showed a loss of ($0.19) EPS, which missed analysts' expectations by ($0.02).
• Despite the earnings downgrades, Gain Therapeutics maintains a consensus "Buy" rating, with a target price set at $7.80 by analysts.

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright reduced their Q3 2025 earnings estimates for Gain Therapeutics in a research report issued to clients and investors on Monday, August 25th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for Gain Therapeutics' current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics' Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.66) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.15) EPS and Q3 2026 earnings at ($0.13) EPS.

Separately, Roth Capital dropped their price objective on shares of Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $7.80.

Gain Therapeutics Stock Performance

GANX traded up $0.11 on Wednesday, hitting $1.99. 599,362 shares of the company's stock were exchanged, compared to its average volume of 390,449. The firm has a market cap of $71.54 million, a PE ratio of -3.16 and a beta of 0.13. Gain Therapeutics has a twelve month low of $0.95 and a twelve month high of $3.19. The stock has a fifty day moving average of $1.70 and a two-hundred day moving average of $1.85. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GANX. Bridgeway Capital Management LLC bought a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $65,000. Kovitz Investment Group Partners LLC bought a new position in shares of Gain Therapeutics in the first quarter valued at approximately $91,000. Northern Trust Corp boosted its holdings in shares of Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after acquiring an additional 39,642 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $198,000. Finally, Dauntless Investment Group LLC acquired a new position in Gain Therapeutics in the first quarter worth approximately $240,000. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.